Meeting
2018 ASCO Annual Meeting
Comparison of outcomes with PD-L1 tumor proportion score (TPS) of 50-74% vs 75-100% in patients with non-small cell lung cancer (NSCLC) treated with first-line PD-1 inhibitors.
Authors
Elizabeth Jimenez Aguilar
Dana-Farber Cancer Institute, Boston, MA
Elizabeth Jimenez Aguilar , Hira Rizvi , Sasha Kravets , Christine A. Lydon , Anika E. Adeni , Safiya Subegdjo , Matthew David Hellmann , Mark M. Awad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9037)
DOI
10.1200/JCO.2018.36.15_suppl.9037
Abstract #
9037
Poster Bd #
360
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Three-year outcomes and correlative analyses in patients with non–small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥ 90% treated with first-line pembrolizumab.
First Author: Biagio Ricciuti
Poster
2020 ASCO Virtual Scientific Program
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status.
First Author: Joao Victor Machado Alessi
Poster
2023 ASCO Annual Meeting
Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.
First Author: Charu Aggarwal
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates